The progress and success of existing core alliances was significant. Milestones were achieved within the alliances with Boehringer Ingelheim, Ono and Novartis. In 2012 Evotec was able to secure multiple pre-clinical milestones totalling € 12.3 m.
EVT Innovate – significant clinical outcomes ahead, Cure X initiative driven by Harvard and Yale
The first Phase III trial on DiaPep277 ® demonstrated the achievement of both its primary and secondary endpoints. Moreover it was announced that the recruitment of the second Phase III trial was closed in September 2012. Results of this second pivotal trial are expected towards the end of 2014.
Roche started a substantial Phase II trial with EVT302 at the end of 2012 aiming at recruiting 450 patients in more than 120 centres worldwide to assess the efficacy and safety of this compound in patients with moderate severity Alzheimer's disease (AD). This clinical trial is one of the very few late-stage trials in this AD patient population. Results are expected during the second half of 2015.Evotec entered into a license agreement with Janssen for its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression. Evotec received an upfront payment of $ 2 m with an additional $ 6 m to be paid upon confirmation of certain pre-clinical properties of the candidates. Evotec could receive up to $ 67 m for the first product depending on certain clinical, regulatory and launch events, as well as additional milestone payments upon successful completion of certain events for additional indications and/or compounds. Evotec could be entitled to an additional $ 100 m in commercial milestones depending on meeting certain sales thresholds and royalties which could be as high as double-digit on certain future sales of royalty bearing products. It is the Company`s expectation that Janssen will initiate Phase II clinical trials in depression during the course of 2013/14.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts